ArticleScientific reports2026
CA1 parvalbumin interneurons display alterations of myelin patterning driven by microgliosis in temporal lobe epilepsy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Temporal lobe epilepsy (TLE) is one of the most common forms of epilepsy, characterized by significant reorganization of hippocampal neuronal circuits. While changes in GABAergic inhibitory circuits are a major feature of this reorganization, other prominent alterations include hippocampal myelination disruption, neuronal loss, and pronounced glial and inflammatory responses. Recent studies have established that parvalbumin (PV +) interneurons in the hippocampus are partially myelinated under normal conditions, representing a notable structural feature of this interneuron subtype. However, whether interneuron myelination becomes altered in TLE has remained unexplored. Using a mouse TLE model, we investigated CA1 PV+ interneurons during epileptogenesis and chronic disease phases, examining numerical density and myelination patterns. We simultaneously tracked microglial responses and oligodendrocyte lineage cell populations (mature oligodendrocytes and their precursors). Our findings reveal that CA1 PV+ interneurons maintain their numerical density throughout disease progression but undergo marked myelination alterations. This dysmyelination occurs concurrently with pronounced microgliosis and changes in the dynamics of oligodendrocyte lineage cell populations, predominantly during epileptogenesis. Notably, pharmacological intervention with GW2580, a CSF1R inhibitor, administered for 8 days around the status epilepticus, prevented both PV+ interneuron myelination alterations and changes in oligodendrocyte lineage cell populations by blocking microglial proliferation. These results establish a link between microgliosis and alterations of myelin patterning in CA1 PV+ interneurons, advancing our understanding of interneuronopathy and TLE pathophysiology. The mechanisms identified share remarkable similarities with those observed in dysmyelinating and neurodegenerative diseases, including multiple sclerosis, suggesting potential common therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.